Based on previous findings, and considering the positive correlation of TSC22D3 with immune cells in this study, it is reasonable to suspect that in cervical cancer, TSC22D3 expression may enhance the immunity of patients by stimulating the activation of immune cells, thereby prolonging their prognosis. This evidence concerns the gene TSC22D3 and cervical cancer.